35 related articles for article (PubMed ID: 1833904)
1. Phosphodiesterase III inhibitors for heart failure.
Amsallem E; Kasparian C; Haddour G; Boissel JP; Nony P
Cochrane Database Syst Rev; 2005 Jan; 2005(1):CD002230. PubMed ID: 15674893
[TBL] [Abstract][Full Text] [Related]
2. Effects of phosphodiesterase 3,4,5 inhibitors on hepatocyte cAMP levels, glycogenolysis, gluconeogenesis and susceptibility to a mitochondrial toxin.
Abdollahi M; Chan TS; Subrahmanyam V; O'Brien PJ
Mol Cell Biochem; 2003 Oct; 252(1-2):205-11. PubMed ID: 14577594
[TBL] [Abstract][Full Text] [Related]
3. Enoximone (MDL 17,043), a phosphodiesterase inhibitor, in the treatment of advanced, unstable chronic heart failure.
Weber KT; Janicki JS; Jain MC
J Heart Transplant; 1986; 5(2):105-12. PubMed ID: 2956397
[TBL] [Abstract][Full Text] [Related]
4. Low-dose enoximone in subjects awaiting cardiac transplantation. Clinical results and effects on beta-adrenergic receptors.
Lee HR; Hershberger RE; Port JD; Rasmussen R; Renlund DG; O'Connell JB; Gilbert EM; Mealey PC; Volkman K; Menlove R
J Thorac Cardiovasc Surg; 1991 Aug; 102(2):246-58. PubMed ID: 1650867
[TBL] [Abstract][Full Text] [Related]
5. [Vasodilatation and positive inotropic effect of the phosphodiesterase inhibitor enoximone].
Holubarsch C; Hasenfuss G; Thierfelder L; Heiss HW; Just H
Z Kardiol; 1991; 80 Suppl 4():35-40. PubMed ID: 1833895
[TBL] [Abstract][Full Text] [Related]
6. Chronic therapy of severe heart failure with enoximone.
Gilfrich HJ; Witzke-Gross J; Römer A
J Cardiovasc Pharmacol; 1989; 14 Suppl 1():S75-7. PubMed ID: 2480490
[TBL] [Abstract][Full Text] [Related]
7. [Enoximone and ventricular arrhythmia in chronic heart failure].
Treese N; Rhein S; Werneyer A; Erbel R; Meyer J
Z Kardiol; 1991; 80 Suppl 4():85-91. PubMed ID: 1833903
[TBL] [Abstract][Full Text] [Related]
8. [Tolerance of enoximone in patients with heart failure].
Gilfrich HJ; Dieterich HA
Z Kardiol; 1991; 80 Suppl 4():93-7. PubMed ID: 1833904
[TBL] [Abstract][Full Text] [Related]
9. [Mechanism of the positive inotropic effect of phosphodiesterase inhibitors].
Scholz H; Dieterich HA; Schmitz W
Z Kardiol; 1991; 80 Suppl 4():1-6. PubMed ID: 1656618
[TBL] [Abstract][Full Text] [Related]
10. [Pharmacology and pharmacokinetics of enoximone].
Jähnchen E; Trenk D
Z Kardiol; 1991; 80 Suppl 4():21-6. PubMed ID: 1833893
[TBL] [Abstract][Full Text] [Related]
11. [Clinico-pharmacologic aspects of therapy with enoximone].
Trenk D; Jähnchen E
Z Kardiol; 1994; 83 Suppl 2():7-14. PubMed ID: 8091828
[TBL] [Abstract][Full Text] [Related]
12. [Positive inotropic substances--therapeutic perspectives].
Erdmann E; Böhm M
Z Kardiol; 1991; 80 Suppl 8():57-62. PubMed ID: 1796636
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
